Apoha Raises $36 Million to Commercialize AI Platform for Molecular Behavior
Updated
Updated · startupfortune.com · Jun 3
Apoha Raises $36 Million to Commercialize AI Platform for Molecular Behavior
3 articles · Updated · startupfortune.com · Jun 3
Summary
$36 million in total funding brings London-based Apoha out of stealth as it shifts from quiet research into commercial deployment of its AI-driven materials discovery platform.
Liquid Brain is designed to measure how molecules behave under changing physical conditions, generating proprietary lab data that Apoha says can feed more predictive AI models.
Apoha says the system works with as little as 10 micrograms of sample, delivers results in about 20 minutes, and has been benchmarked across more than 200 clinical-stage antibodies.
The company is starting with antibody developability, where early detection of viscosity, aggregation and formulation risks can prevent costly late-stage failures.
The raise highlights a broader AI funding turn toward deep-tech platforms that combine wet labs, hardware and machine learning to build defensible data moats.
With 90% precision in predicting drug failures, could this technology make costly clinical trials a thing of the past?
Apoha's tech predicts molecular behavior, but what are the fundamental limits of this new 'Liquid State Intelligence'?
How will a new 'language of matter' change R&D now that AI can finally 'feel' the physical world?
Apoha Secures $36M Series A to Revolutionize Molecular Science with VIBE® and Liquid State Intelligence
Overview
Apoha, a deep tech company in biotech and life sciences, has emerged from stealth with a $36 million Series A funding led by Singular and other investors. This investment validates Apoha’s unique 'Liquid State Intelligence' platform, which addresses a critical gap in molecular science by enabling machines to perceive properties like how a drug dissolves or a material wears—capabilities beyond current visual or language AI. With this funding, Apoha is set to scale its innovative technology, aiming to transform how matter is understood and interacted with, and to accelerate breakthroughs in drug development and materials science.